Facts & Figures
Bayer HealthCare
The Company combines the global activities of the divisions Animal Health, Bayer Schering Pharma, Consumer Care and Medical Care. More than 50,000 people are employed by Bayer HealthCare worldwide.
Our aim is to discover and manufacture innovative products that will improve human and animal health worldwide. Our products enhance well-being and quality of life by diagnosing, preventing and treating disease.
- Sales 2008: 15,407 Euro million
- Workforce: 53,100 worldwide
- Operating profit 2008: 2,181 Euro million
- Headquarters: Leverkusen, Germany
Divisions of Bayer HealthCare
| Management | Based in |
|---|
Animal Health
| Lykele van der Broek | Monheim, Germany |
| Bayer Schering Pharma | Andreas Fibig | Berlin, Germany |
Consumer Care
| Gary S. Balkema | Morristown, USA |
Medical Care
| Sandra E. Peterson | Tarrytown, New York, USA |
Executive Committee
Chairman: Arthur J. Higgins
Members of the Executive Committee
- Gary S. Balkema
- Werner Baumann
- Lykele van der Broek
- Prof. Dr. Andreas Busch
- Andreas Fibig
- Dr. Hartmut Klusik
- Dr. Ulrich Köstlin
- Sandra E. Peterson
- Dr. Kemal Malik
Sales 2008
Sales of the HealthCare subgroup grew by 4.1 percent in 2008, to € 15,407 million. Adjusted for currency and portfolio effects, sales climbed by 6.9 percent. The increase was due to the positive business performance of both segments.
| 2008 | 2007 | Change
|
| |
€ million |
€ million |
% |
| Bayer HealthCare |
15,407 |
14,807 |
4.1
|
- Division Animal Health
|
963 |
956 |
0.7
|
- Division Consumer Care
|
2,770 |
2,634 |
5.2 |
- Division Diabetes Care
|
970 |
950 |
2.1 |
- Division Bayer Schering Pharma
|
10,704 |
10,267 |
4.3
|
Performance 2008
Sales of our Pharmaceuticals segment increased by 4.3 percent in 2008 to €10,704 million (2007: €10,267 million). Adjusted for currency and portfolio effects, sales rose by 7.1 percent.
Our Consumer Health segment improved sales by 3.6 percent to €4,703 million (2007: €4,540 million). After adjusting for currency and portfolio effects, the increase came to 6.3 percent, with all divisions contributing similarly to growth.
In the Consumer Care Division, sales advanced by 5.2 percent to €2,770 million (2007: €2,634 million). The increase came in part from the calcium supplement Citracal® acquired in October 2007, the Sagmel business in eastern Europe acquired in June 2008 and, since September 2008, the Topsun acquisition in China. Sales rose by 6.2 percent on a currency- and portfolio-adjusted basis. Bepanthen® / Bepanthol® (currency-adjusted +20.7 percent), Canesten® (currency-adjusted +16.1 percent) and One-A-Day® (currency-adjusted +13.8 percent) developed particularly well.
Sales of our Diabetes Care Division rose by 2.1 percent to €970 million (2007: €950 million). After adjusting for shifts in exchange rates, the increase came to 6.4 percent. The blood glucose monitoring systems of our Contour® product line performed very well in the market, with sales up by a currency-adjusted 18.4 percent. This growth was partly due to substitution of the older Elite® systems, sales of which declined by a currency-adjusted 26.5 percent. Also contributing to the positive business performance of Diabetes Care was our Contour® TS product line, launched in the second half of 2007, which generated sales of €25 million in 2008 (2007: €4 million).
Animal Health recorded sales of €963 million (2007: €956 million). On a currency-adjusted basis, business expanded by 6.4 percent. Our Advantage® product line for flea and tick control performed particularly well (currency-adjusted +11.1 percent). We also benefited from higher sales of our Drontal® line of dewormers (currency-adjusted +5.5 percent).
Research & Development 2008
In 2008 we invested €1,742 million (2007: €1,700 million) in research and development in the Pharmaceuticals and Consumer Health segments to lay the foundations for the introduction of further innovative products in the subgroup’s expanding markets. This represented about 66 percent of the Bayer Group’s entire research and development expenditures and was equivalent to 11.3 percent of sales.
